Small Cap Feast
Small Cap Feast – 21st March 2017
Dish of the Day:
Medica Group has been admitted to the Official List. £121m raised at 135p.
Medica Group has been admitted to the Official List. £121m raised at 135p.
Off the Menu:
No AIM Leavers Today
No AIM Leavers Today
What’s Cooking in the IPO Kitchen?
First Sentinel—Investment company expecting NEX admission/introduction on 24 March. £636k raised pre-IPO.
BioPharma Credit—Expected Gross Initial Acquisition Proceeds now c.$338m. Gross Cash Proceeds capped at $423m with placing and open offer. Results expected 23 March with admission now due 30 march.
Tufton Oceanic Assets- The Company intends to invest in a diversified portfolio of second hand commercial sea-going vessels where the Investment Manager believes that an attractive opportunity exists in shipping. $150m raise. Admission 3 April.
Good Energy (GOOD.L) 255p £42m
FYDec16 results from the renewable electricity supplier and generator. Revenue +41% to £90.4m. EPS 9.1p from 1.4p loss. Final div unchanged at 2.3p. Net debt £52.5p. Separately Good Energy has signed an agreement with DONG Energy which will see it source offshore wind power for its customers for the first time. The deal secures 12% of the output of the 210MW Westermost Rough Wind Farm operated by the Danish energy group in the North Sea, enough renewable electricity to power more than 26,000 average homes. The agreement is for an initial period of 12 months but is likely to be extended for the longer term as part of the wider co-operation between the two companies. It is also intended that the volume of power purchased by Good Energy from DONG will increase over time. FYDec17E £102.3m and PBT of £2.08m.
Berkeley Energia (BKY.L) 57p £145.1m
The European Union has welcomed the development of the Salamanca mine by approving the Company’s offtake agreement for the sale of the first production. In November 2016, the Company entered into a sales agreement with Curzon Resources Limited, formerly known as Interalloys Trading Limited, for a total of two million pounds of uranium over a five-year period, with scope to increase to a total of three million pounds. The agreement is for an average fixed price of US$43.78 per pound of contracted and optional volumes, which compares favourably to the current spot price of US$25 per pound and establishes a strong cash margin above the steady state production costs of around US$15 per pound. On track for first production in late 2018.
Judges Scientific (JDG.L) 1,565p £95.65m
FYDec16 results from the group involved in the buy and build of scientific instrument businesses. Revenues up 2% to a record £57.3 million. A record four acquisitions completed during the year: CoolLED, Dia-Stron, Fire Instrumentation and Research Equipment (“FIRE”) and EWB Solutions for £9.0 million; Final dividend of 18.5p, making a total 27.5p for the year, an increase of 10%; covered 3.1 times by adjusted earnings; Trading performance ‘disappointing’ with adjusted operating profit of £7.1 million (2015: £9.3 million); “Judges commences 2017 with a solid financial position, four new businesses, a strong order book and positive order intake since the start of the year, all of which provides a platform for a year of progress.” FYDec17E £60.6m and EPS of 100.1p.
XL Media (XLM.L) 111.5p £223.4m
The provider of digital performance marketing services, announced that Dau-Up, its wholly owned subsidiary, has been granted official status as an Instagram Partner, specialising in advertising technology. The Instagram Partner Program has recognised Dau-Up for its leading position in mobile user acquisition, and identified its proven delivery of improved performance for its partners on the Instagram platform. Dau-Up’s proprietary technology “Rampix” is uniquely tailored for acquiring users for games and mobile apps, leveraging data-driven automation. The combination of Dau-Up’s technology and skills with the performance models offered by the Group, provides a unique opportunity to XLMedia’s customers to attract the right campaign audience. FYDEC17E rev £106.6m, EPS 10.5p, Div 607p.
Fevertree Drinks (FEVR.L) 1380p £1.68bn
FYDec16 results from the supplier of premium carbonated mixers. Revenue up 73% to £102.2m. Gross profit margin of 55.2% (2015: 52.1%). Adjusted EBITDA up 97% to £35.8m (2015: £18.2m). Robust balance sheet with net cash at year end of £26.9m (2015: £11.6m). Final dividend of 4.71 pence per share recommended to shareholders, bringing total dividend to 6.25 pence per share (2015: 3.08 pence per share). “We have had an encouraging start to 2017 and I look forward to working with my Board colleagues and the wider Fever-Tree team to continue to deliver growth” FYDec17E rev of £120m and EPS of 25.92p. >50x PE.
Keras Resources (KRS.L) 0.4p £6.88m
Keras has announced plans for the proposed listing of the Company’s Australian gold assets on the ASX. Keras and Pharmanet have today entered into a binding agreement whereby Pharmanet will acquire 100% of Keras Australia; Consideration for the Transaction will be satisfied via the issue of ordinary shares in Pharmanet, subject to the achievement of certain agreed milestones. In conjunction with the Transaction, Pharmanet will complete a capital raising, by way of prospectus, targeting a raising of A$8 million, to undertake a major drilling and exploration programme at the Warrawoona Gold Project, to undertake initial Scoping Studies and to repay the Company’s Acquisition Finance Facility
Flowgroup (FLOW.L) 3.88p £12.3m
On 8 February, the Company announced that it was actively pursuing the sale of Flow Energy Limited and can now report that, following that announcement, it received a number of indicative offers for that part of the Group. The Company announces that it has selected a preferred bidder and has entered into an exclusivity agreement with this party. Whilst there can be no guarantee that the sale of Flow Energy Limited will complete with this party, or that the sale of Flow Energy Limited will complete at all, the Company expects to make a further announcement in the coming weeks. Any disposal would be conditional on shareholder approval. FYDec16E £88.6m rev and £25m PBT loss.
mporium Group (MPM.L) 14.88p £76.49m
The mobile commerce specialist has announced the results of a placing. £3.05m raised at 15p. The net proceeds of the Placing will primarily be used to enable the Group to continue with its IMPACT and INSIGHTS product roll-out, in line with the Group’s existing growth strategy. IMPACT is digital advertising technology that enables campaigns to be managed across Google AdWords, Facebook, Instagram and YouTube, by leveraging in real-time, events such as TV content, sports, news, weather and social media. INSIGHTS continues to evolve into a decision making support tool that delivers actionable information to enable users to manage their websites and the digital advertising campaigns that drive web traffic to their websites.
Hunters Property (HUNT.L) 58.38p £16.7m
One of the UK’s largest national sales and lettings agency and franchise businesses, announced the proposed acquisition of the franchising business and related assets of Besley Hill Franchising Limited, the Seller, for a total consideration of £2.5 million together with a placing of new Ordinary Shares at 55p to raise up to £1.32 million which will be used to finance part of the cost of the Acquisition. An accelerated bookbuild will commence today. Trading ahead of market expectations. Network income for 2016 up 17% to £35.4m. We could find no market forecasts.
The Brighton Pier Group (PIER.L) 109.5p £34.78m
HY Dec 16 results. ‘This has been a transformational period for the Group. The acquisition of Brighton Palace Pier has delivered a strong financial performance for the Group with its first summer trading period in this half year set of results. I believe there are exciting opportunities to further develop the Pier business over the coming years. We continue to make good progress rationalising the Bars division together with driving operational and financial improvements across the estate.’ Sales £17.74m. Adjusted EBITDA £3.5m. Basic EPS of 8.2p. Trading for the first half is in line with market expectations. FYJun17 rev £3.05m, EPS 7.53p. 14.6x PE,
0203 764 2344
*A corporate client of Hybridan LLP
This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to any such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific person or entity and is not a personal recommendation to any such person or entity. Recipients should reach an individual investment decision, based upon their respective financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.
The information contained in this document is based on materials and sources that are believed to be reliable; however, such information has not been independently verified and therefore it is not possible to confirm such information as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information contained in this document, nor should it be relied upon as such.
The content of this document includes market commentary and other information which we have prepared in relation to the company referred to in this document, which is our broking client. The provision of this document to you constitutes a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of Regulation 600/2014/EU (MIFID II Regulation).
Any and all opinions expressed are current as of the date appearing on this face of this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.
This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, constitutes non-independent research (as such term is defined in the Financial Conduct Authority’s Conduct of Business Sourcebook to reflect the requirements of the MIFID II Regulation and Directive 2014/65/EU (known as MIFID II)). The individuals who prepared this document may be interested in shares in the company concerned and/or other companies within its sector, may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.
In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority’s Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as relevant persons). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority’s Conduct of Business Sourcebook.
Neither this document, nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.
Where possible this document is made available to all relevant recipients at the same time. Dissemination of research by Hybridan LLP is monitored to ensure that it is only provided to relevant persons. Research prepared by Hybridan LLP is not intended to be received and/or used by any person who is a retail client.
Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.
This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.
MIFID II status of Hybridan LLP research
The cost of production of our corporate research is met by retainers from our corporate broking clients. In addition, from time to time we issue further communications as market commentary (such as our daily newsletter, Small Cap Breakfast), which we consider to constitute a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of the MIFID II Regulation.
Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.
If you would like to unsubscribe, please email email@example.com with “unsubscribe me”.